ATE208377T1 - Substituierte benzylaminopiperloin verbindungen - Google Patents

Substituierte benzylaminopiperloin verbindungen

Info

Publication number
ATE208377T1
ATE208377T1 AT96914375T AT96914375T ATE208377T1 AT E208377 T1 ATE208377 T1 AT E208377T1 AT 96914375 T AT96914375 T AT 96914375T AT 96914375 T AT96914375 T AT 96914375T AT E208377 T1 ATE208377 T1 AT E208377T1
Authority
AT
Austria
Prior art keywords
benzylaminopiperloin
substituted
compounds
substituted benzylaminopiperloin
benzylaminopiperloin compounds
Prior art date
Application number
AT96914375T
Other languages
English (en)
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE208377T1 publication Critical patent/ATE208377T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96914375T 1995-08-24 1996-06-10 Substituierte benzylaminopiperloin verbindungen ATE208377T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (1)

Publication Number Publication Date
ATE208377T1 true ATE208377T1 (de) 2001-11-15

Family

ID=11004362

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96914375T ATE208377T1 (de) 1995-08-24 1996-06-10 Substituierte benzylaminopiperloin verbindungen
AT01108350T ATE258166T1 (de) 1995-08-24 1996-06-10 Substituierte benzylaminpiperidin-verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01108350T ATE258166T1 (de) 1995-08-24 1996-06-10 Substituierte benzylaminpiperidin-verbindungen

Country Status (41)

Country Link
US (1) US6506775B1 (de)
EP (2) EP0861235B1 (de)
JP (1) JP3084069B2 (de)
KR (1) KR100288673B1 (de)
CN (1) CN1153764C (de)
AP (1) AP643A (de)
AR (1) AR006305A1 (de)
AT (2) ATE208377T1 (de)
AU (1) AU702698B2 (de)
BG (1) BG64126B1 (de)
BR (1) BR9609989A (de)
CA (1) CA2227814C (de)
CO (1) CO4480738A1 (de)
CZ (1) CZ297543B6 (de)
DE (2) DE69631390T2 (de)
DK (2) DK0861235T3 (de)
DZ (1) DZ2086A1 (de)
ES (2) ES2163017T3 (de)
HR (1) HRP960386B1 (de)
HU (1) HU225480B1 (de)
IL (1) IL119078A (de)
IS (1) IS1947B (de)
MA (1) MA23961A1 (de)
MX (1) MX9801467A (de)
MY (1) MY114800A (de)
NO (1) NO310720B1 (de)
NZ (1) NZ308207A (de)
OA (1) OA10666A (de)
PE (2) PE20010700A1 (de)
PL (1) PL186773B1 (de)
PT (2) PT861235E (de)
RO (1) RO119299B1 (de)
RU (1) RU2152930C2 (de)
SI (2) SI0861235T1 (de)
SK (1) SK282925B6 (de)
TN (1) TNSN96107A1 (de)
TR (1) TR199800300T1 (de)
TW (1) TW340842B (de)
UA (1) UA48981C2 (de)
WO (1) WO1997008144A1 (de)
YU (1) YU49122B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
AU3572800A (en) * 1999-05-06 2000-11-21 Pfizer Products Inc. Substituted benzolactam compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
WO2000071538A2 (en) * 1999-05-21 2000-11-30 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
ATE257477T1 (de) * 1999-10-18 2004-01-15 Pfizer Prod Inc Verfahren zur herstellung von zyklischen piperidinylaminomethyl-trifluoromethyl- etherderivaten
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
KR100885986B1 (ko) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
BRPI0409211A (pt) 2003-04-18 2006-03-28 Lilly Co Eli composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
MXPA06013484A (es) * 2004-05-21 2007-01-23 Pfizer Prod Inc Metabolitos de (+)-(2s, 3s)-3-(2- metoxi-5- trifluorometoxibencilamino) -2-fenil- piperidina.
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
ZA200800440B (en) 2005-07-15 2009-12-30 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (de) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amidsubstituierte Indazole als Poly-(ADP-Ribose)-Polymerase (PARP)-Hemmer
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
JP5511080B2 (ja) 2008-03-31 2014-06-04 興和株式会社 １，３−ジヒドロイソベンゾフラン誘導体
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
EP2429295B1 (de) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (de) 2011-04-21 2014-02-26 Piramal Enterprises Limited Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
BR9205807A (pt) * 1991-03-26 1994-06-28 Pfizer Preparação estéreo-seletiva de piperidinas substituidas
BR9206161A (pt) * 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
US5886011A (en) 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
ES2180693T3 (es) * 1995-12-21 2003-02-16 Pfizer 3-((bencil 5-sustituido)amino)-2-fenilpiperidinas como antagonistas de la sustancia p.
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
DK0861235T3 (da) 2001-12-27
RO119299B1 (ro) 2004-07-30
DK1114817T3 (da) 2004-04-26
WO1997008144A1 (en) 1997-03-06
HRP960386B1 (en) 2002-04-30
NZ308207A (en) 1998-07-28
PE20010700A1 (es) 2001-07-09
RU2152930C2 (ru) 2000-07-20
NO310720B1 (no) 2001-08-20
YU49122B (sh) 2004-03-12
TR199800300T1 (xx) 1998-06-22
KR100288673B1 (ko) 2001-05-02
CN1193961A (zh) 1998-09-23
IS1947B (is) 2004-10-13
JP3084069B2 (ja) 2000-09-04
EP0861235B1 (de) 2001-11-07
MA23961A1 (fr) 1997-04-01
DE69631390T2 (de) 2004-11-25
CZ52198A3 (cs) 1999-01-13
IS4644A (is) 1997-12-30
TW340842B (en) 1998-09-21
TNSN96107A1 (fr) 2005-03-15
HUP9901159A3 (en) 2000-05-29
HRP960386A2 (en) 1998-04-30
PL325332A1 (en) 1998-07-20
CO4480738A1 (es) 1997-07-09
IL119078A (en) 2003-11-23
CN1153764C (zh) 2004-06-16
HK1014935A1 (en) 1999-10-08
PT1114817E (pt) 2004-05-31
SK20798A3 (en) 1999-03-12
NO980751D0 (no) 1998-02-23
YU47896A (sh) 1998-12-23
AU702698B2 (en) 1999-03-04
AP643A (en) 1998-04-24
ES2163017T3 (es) 2002-01-16
PE1398A1 (es) 1998-02-27
BG102288A (en) 1998-09-30
UA48981C2 (uk) 2002-09-16
PT861235E (pt) 2002-03-28
HUP9901159A2 (hu) 1999-07-28
IL119078A0 (en) 1996-11-14
CZ297543B6 (cs) 2007-02-07
DE69616817T2 (de) 2002-04-04
CA2227814C (en) 2002-12-31
US6506775B1 (en) 2003-01-14
BR9609989A (pt) 1999-07-06
EP1114817B1 (de) 2004-01-21
AP9600850A0 (en) 1996-10-31
SI1114817T1 (en) 2004-06-30
ATE258166T1 (de) 2004-02-15
EP0861235A1 (de) 1998-09-02
ES2211684T3 (es) 2004-07-16
OA10666A (en) 2002-11-25
EP1114817A1 (de) 2001-07-11
DE69616817D1 (de) 2001-12-13
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
CA2227814A1 (en) 1997-03-06
AR006305A1 (es) 1999-08-25
AU5776996A (en) 1997-03-19
DZ2086A1 (fr) 2002-07-22
PL186773B1 (pl) 2004-02-27
MY114800A (en) 2003-01-31
MX9801467A (es) 1998-05-31
NO980751L (no) 1998-02-23
BG64126B1 (bg) 2004-01-30
KR19990044077A (ko) 1999-06-25
JPH10510554A (ja) 1998-10-13
SK282925B6 (sk) 2003-01-09
SI0861235T1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
DE69616817D1 (de) Substituierte benzylaminopiperloin verbindungen
ATE298739T1 (de) Calcylitische verbindungen
ID16345A (id) Senyawa-senyawa heterosiklik
ATE208762T1 (de) Parasitizide verbindungen
FI972970A0 (fi) Uusia yhdisteitä
BR9600534A (pt) Novos compostos
BR9609320A (pt) Cianofeniluracilas substituidas
ATE222893T1 (de) Triazinylaminostilben verbindungen
BR9600251A (pt) Composto
DE69808403D1 (de) Tetradecachlorcyclohexasilandianon enthaltende Verbindungen
BR9610214A (pt) Compostos farmacéuticos
NO982566D0 (no) Forbindelser
DE69531522D1 (de) Heterozyklische Verbindungen
ATE225364T1 (de) Bromotiacumicin verbindungen
NO974170D0 (no) Polyazacykloalkan-forbindelser
ATE219488T1 (de) Pestizide tris-oximino heterocyclische verbindungen
DE69801556D1 (de) Spirocyclische Verbindungen
BR9601295A (pt) Composto
BR9609319A (pt) Carbonilaminofeniluracilas substituídas
BR9608890A (pt) N-metilenotiouréias substituídas
BR9611576A (pt) Composto
NO965448L (no) Farmasöytiske forbindelser
DE69632176D1 (de) Anti-inflammatorische Verbindungen
BR9603376A (pt) Tetrahidro-5-nitro-pirimidinas substituídas
DE59607732D1 (de) Substituierte benzylidencyanessigester

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee